Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02500979 · ClinicalTrials.gov registry record · Phase 1
Effect of a Fixed Pramlintide: Insulin Dose Ratio on Postprandial Glucose in Type 1 Diabetes Mellitus
A Phase 1 study, sponsored by AstraZeneca.
- Completed
- Registry status
- Phase 1
- Development phase
- 34
- Enrollment target
NCT02500979 is a Phase 1 study that has completed, run by AstraZeneca. The registered enrollment target is 34 participants.
The verdict
NCT02500979, a Phase 1 study, has completed, sponsored by AstraZeneca.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 34 participants
- Enrollment target
Study Summary
This study is designed to investigate the clinical efficacy and safety of pramlintide co-administered as a fixed-dose ratio with basal-bolus SC insulin, delivered simultaneously via 2 separate pumps, in subjects with type 1 diabetes who are failing to achieve the desired level of glycemic control using insulin therapy.
Interventions
- DRUG Placebo
- DRUG Pramlintide acetate
- DRUG Lispro insulin U-100
- DRUG Regular insulin U-100
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 34 participants |
| Start Date | 2015-08-17 |
| Est. Completion | 2016-08-05 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02500979
The ClinicalTrials.gov registry entry for NCT02500979 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 34 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is AstraZeneca, which has 1,285 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Placebo is the first listed.
NCT02500979 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02500979 about?
NCT02500979 is a clinical study titled "Effect of a Fixed Pramlintide: Insulin Dose Ratio on Postprandial Glucose in Type 1 Diabetes Mellitus". This study is designed to investigate the clinical efficacy and safety of pramlintide co-administered as a fixed-dose ratio with basal-bolus SC insulin, delivered simultaneously via 2 separate pumps, in subjects with type 1 diabetes who are failing to achieve the desired level of glycemic control us...
What is the current status of trial NCT02500979?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 34 participants. The study started on 2015-08-17. Estimated completion is 2016-08-05.
What interventions are being tested in trial NCT02500979?
The interventions under investigation include: Placebo (DRUG), Pramlintide acetate (DRUG), Lispro insulin U-100 (DRUG), Regular insulin U-100 (DRUG).
Who is sponsoring clinical trial NCT02500979?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.